Medicaid Drug Utilization Review (DUR) Board Meeting Agenda for February 18, 2010

The Drug Utilization Review (DUR) Board will meet February 18, 2010, from 9:00 a.m. to 4:30 p.m., Meeting Room 6, Concourse, Empire State Plaza, Albany, New York.

Agenda Items:

1. Drug Utilization Presentations and Discussion of the following drugs/drug classes:

  1. Topical Steroids Utilization Review
  2. Aclovate (alclometasone dipropionate), alclometasone dipropionate, amcinonide, Apexicon (diflorasone diacetate) , Apexicon E (diflorasone diacetate/emollient), betamethasone dipropionate, betamethasone valerate, clobetasol propionate, Clobex (clobetasol propionate), Cloderm (Clocortolone pivalate), Cormax (clobetasol propionate), Cutivate (fluticasone propionate), Derma-Smoothe/FS (fluocinolone acetonide), Dermatop (prednicarbate), Desonate (desonide), desonide, Desowen (desonide), desoximetasone, diflorasone diacetate, Diprolene (betamethasone dipropionate/propylene glycol), Diprolene AF (betamethasone dipropionate/ propylene glycol), Elocon (mometasone furoate), fluocinolone acetonide, fluocinonide, fluocinonide-e (fluocinonide/emollient), fluticasone propionate, halobetasol propionate, Halog (halcinonide), hydrocortisone, hydrocortisone acetate, hydrocortisone valerate, Kenalog (triamcinolone acetonide), Lokara (desonide), Luxiq (betamethasone valerate), mometasone furoate, Olux (clobetasol propionate), (Olux-Olux-E complete pack (clobetasol propionate/emollient), Pandel (hydrocortisone probutate), prednicarbate, Temovate (clobetasol propionate), Temovate Emollient (clobetasol propionate/emollient), Texacort (hydrocortisone), Topicort (desoximetasone), triamcinolone acetonide, Ultravate (halobetasol propionate), Vanos (fluocinonide), Verdeso (desonide), Westcort (hydrocortisone valerate)
  1. Topical Antifungals Utilization Review
  2. clotrimazole, ciclopirox olamine, econazole nitrate, Ertaczo (sertaconazole nitrate), Exelderm (sulconazole nitrate), Extina (ketoconazole), ketoconazole, Lamisil (terbinafine HCL), Lamisil AT (terbinafine HCL), Loprox (ciclopirox), Mentax (butenafine HCL), Micatin (miconazole nitrate), miconazole nitrate, Naftin (naftifine HCL), Nyamyc (nystatin), nystatin, Nystop (nystatin), Oxistat (oxiconazole nitrate), Pedi-Dri (nystatin), Q-Naftate (tolnaftate), terbinafine, Tinactin (tolnaftate), tolnaftate, Xolegel (ketoconazole)
  1. Ophthalmic Antibiotics Utilization Review
  2. AzaSite (azithromycin ophthalmic solution), bacitracin eye ointment, bacitracin/polymyxin-b eye ointment, Bleph-10 solution (sulfacetamide sodium), Blephamide (sodium sulfacetamide/prednisolone acetate), Cortisporin eye drops (neomycin/polymyxin-b/hydrocortisone), erythromycin eye ointment, gentamicin sulfate ointment, gentamicin sulfate solution, Maxitrol (neo/polymyxin-b/ dexamethasone), Neocidin solution, neomycin/bacitracin/polymyxin-b, neomycin/bacitracin/polymyxin-b/hydrocortisone, neomycin/polymyxin-b/ dexamethasone, neomycin/polymyxin-b/gramicidin solution, neomycin/polymyxin-b/ hydrocortisone solution, Poly-Pred (neomycin/polymyxin-b/prednisolone), Polytrim (polymyxin-b /trimethoprim), polymyxin-b sulfate/trimethoprim solution, Pred-G (gentamicin/prednisolone), Pred-G SOP (gentamicin/prednisolone), sulfacetamide sodium, sodium sulfacetamide/prednisolone, Tobradex (tobramycin sulfate/dexamethasone), tobramycin sulfate solution, tobramycin sulfate/dexamethasone, Tobrex (tobramycin ophthalmic ointment), Zylet (tobramycin/ loteprednol ophthalmic suspension)
  1. Triptans Utilization Review
  2. Amerge (naratriptan), Axert (almotriptan), Frova (frovatriptan), Imitrex (sumatriptan succinate), Maxalt, Maxalt MLT, (rizatriptan), Relpax (eletriptan hydrobromide), sumatriptan succinate, Treximet (sumatriptan/naproxen), Zomig, Zomig-ZMT (zolmitriptan)
  1. Montelukast Utilization Review in Allergic Rhinitis

2. Psychiatric Services and Clinical Knowledge Enhancement System (PSYCKES) Update

3. Prescriber Education Program (PEP) Update

4. Medicaid DUR Activities Report

5. Medication Therapy Management (MTM) Program Update

Agenda Timeline (subject to change)

Time Agenda Topic
9:00 - 9:15 Welcome and Introductions
9:15 - 10:15 Public Comment Period*
10:15 - 11:00 Topical Steroids Utilization Review
11:00 - 11:45 Topical Antifungals Utilization Review
11:45 - 12:00 Break
12:00 - 12:30 Ophthalmic Antibiotics Utilization Review
12:30 - 1:30 Lunch
1:30 - 2:00 Psychiatric Services and Clinical Knowledge Enhancement System (PSYCKES)
2:00 - 2:30 Montelukast Utilization Review in Allergic Rhinitis
2:30 - 3:00 Triptans Utilization Review
3:00 - 3:15 Prescriber Education Program (PEP) Update
3:15 - 3:30 Break
3:30 - 4:00 Medicaid DUR Activities Report
4:00 - 4:15 Medication Therapy Management (MTM) Program Update
4:15 - 4:30 Final Comments/Adjournment

*Interested parties must notify the Drug Utilization Review Manager at least one (1) week prior to the meeting of their request to address the DUR Board during the public comment period. Requests may be made by calling 518-486-3209 or e-mailing (please reference DUR Board). Public comments are limited to the specific topics on the agenda, must be brief (2 minutes), and the total comment period will not exceed sixty (60) minutes. All written statements, up to two (2) pages in length must be received up to one (1) week in advance of the meeting. These statements should summarize key points.

NOTE: For those submitting information greater than two (2) pages in length for DUR Board review and consideration must do so at least two (2) weeks prior to the meeting date or the Board may not have ample time to review the information.

Posted 01/27/2010